C4 Therapeutics, Inc. (CCCC)
USD 3.66
(-9.75%)
USD 3.66
(-9.75%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 20.75 Million | 31.09 Million | 45.78 Million | 33.19 Million | 21.38 Million | 19.36 Million |
| Cost of Revenue | 117.7 Million | 7.57 Million | 2.9 Million | 77.46 Million | 47.66 Million | 28.59 Million |
| Gross Profit | -96.95 Million | 23.52 Million | 42.87 Million | -44.27 Million | -26.28 Million | -9.22 Million |
| Operating Expenses | 159.78 Million | 160.63 Million | 127.91 Million | 93.64 Million | 56.83 Million | 35.75 Million |
| Selling, General and Administrative Expenses | 42.08 Million | 42.78 Million | 33.25 Million | 15.2 Million | 8.77 Million | 7.16 Million |
| Research and Development Expenses | 117.7 Million | 117.84 Million | 94.66 Million | 78.44 Million | 48.05 Million | 28.59 Million |
| Other Expenses | - | - | - | - | 325 Thousand | -7000.00 |
| Cost and Expenses | 159.78 Million | 160.63 Million | 127.91 Million | 93.64 Million | 56.83 Million | 35.75 Million |
| Operating Income | -139.03 Million | -129.53 Million | -82.13 Million | -60.44 Million | -35.45 Million | -16.38 Million |
| Interest Expense | 1.37 Million | 2.21 Million | 2.14 Million | 1.22 Million | - | - |
| Income Tax Expense | 1.28 Million | -1.67 Million | 2.14 Million | -626 Thousand | 804 Thousand | 678 Thousand |
| Earnings before Tax | -131.21 Million | -128.17 Million | -83.89 Million | -66.96 Million | -33.29 Million | -15.71 Million |
| Net Income | -132.49 Million | -126.49 Million | -86.03 Million | -66.33 Million | -34.09 Million | -15.71 Million |
| Earnings Per Share Basic | -2.67 | -2.59 | -1.87 | -1.54 | -0.79 | -1.06 |
| Earnings Per Share Diluted | -2.67 | -2.59 | -1.87 | -1.54 | -0.79 | -1.06 |
| Weighted Average Shares Outstanding | 49.64 Million | 48.86 Million | 46.04 Million | 43.05 Million | 42.98 Million | 14.78 Million |
| Weighted Average Shares Outstanding (Diluted) | 49.64 Million | 48.86 Million | 46.04 Million | 43.05 Million | 42.98 Million | 42.09 Million |
| Gross Margin | -4.67 | 0.76 | 0.94 | -1.33 | -1.23 | -0.48 |
| EBIT Margin | -5.88 | -4.05 | -1.75 | -1.76 | -1.58 | -0.78 |
| Profit Margin | -6.38 | -4.07 | -1.88 | -2.00 | -1.59 | -0.81 |
| EBITDA | -122.1 Million | -124.28 Million | -78.84 Million | -62.89 Million | -30.55 Million | -15.11 Million |
| Earnings Before Tax Margin | -6.70 | -4.17 | -1.79 | -1.82 | -1.66 | -0.85 |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 Q3 | 2023 FY | 2023 Q2 |
|---|---|---|---|---|---|---|
| Revenue | 15.36 Million | 12 Million | 3.03 Million | 3.26 Million | 20.75 Million | 11.07 Million |
| Cost of Revenue | 2.05 Million | 2.04 Million | 2.02 Million | 1.69 Million | 7.73 Million | 1.99 Million |
| Gross Profit | 13.3 Million | 9.96 Million | 1.01 Million | 1.57 Million | 13.01 Million | 9.07 Million |
| Operating Expenses | 43.6 Million | 33.44 Million | 35.25 Million | 38.99 Million | 152.05 Million | 38.88 Million |
| Selling, General and Administrative Expenses | 11.76 Million | 9.69 Million | 10.28 Million | 8.6 Million | - | 10.53 Million |
| Research and Development Expenses | 31.83 Million | 23.75 Million | 22.53 Million | 30.39 Million | - | 28.34 Million |
| Other Expenses | -31.83 Million | - | 2.43 Million | - | - | - |
| Cost and Expenses | 43.6 Million | 33.44 Million | 35.25 Million | 40.68 Million | 159.78 Million | 38.88 Million |
| Operating Income | -28.24 Million | -21.44 Million | -32.21 Million | -37.42 Million | -139.03 Million | -27.8 Million |
| Interest Expense | - | - | - | -2.41 Million | 1.37 Million | -167 Thousand |
| Income Tax Expense | -2.05 Million | -2.04 Million | -2.02 Million | 277 Thousand | 1.28 Million | -1 Million |
| Earnings before Tax | -24.66 Million | -17.71 Million | -28.36 Million | -34.47 Million | -131.21 Million | -26.03 Million |
| Net Income | -24.66 Million | -17.71 Million | -28.36 Million | -34.75 Million | -132.49 Million | -27.03 Million |
| Earnings Per Share Basic | -0.35 | -0.26 | -0.41 | -0.68 | - | -0.55 |
| Earnings Per Share Diluted | -0.35 | -0.26 | -0.41 | -0.68 | - | -0.55 |
| Weighted Average Shares Outstanding | 69.62 Million | 68.81 Million | 68.43 Million | 51.21 Million | 49.64 Million | 49.21 Million |
| Weighted Average Shares Outstanding (Diluted) | 69.62 Million | 68.81 Million | 68.43 Million | 51.21 Million | 49.64 Million | 49.21 Million |
| Gross Margin | 0.87 | 0.83 | 0.33 | 0.48 | 0.63 | 0.82 |
| EBIT Margin | -1.84 | -1.79 | -10.60 | -10.96 | - | -2.51 |
| Profit Margin | -1.61 | -1.48 | -9.33 | -10.66 | -6.38 | -2.44 |
| EBITDA | -28.24 Million | -21.44 Million | -32.21 Million | -35.73 Million | - | -27.8 Million |
| Earnings Before Tax Margin | -1.84 | -1.79 | -10.60 | -11.48 | -6.70 | -2.51 |
HLLY
FPLSF
HQY
VAGNF
3002
EUSP